pregabalin mylan pharma
mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptika, - epilepsypregabalin mylan läkemedel är indicerat som tilläggsbehandling för vuxna med partiella anfall med eller utan sekundär generalisering. generaliserad Ångest disorderpregabalin mylan pharma är indicerat för behandling av generaliserat ångestsyndrom (gad) hos vuxna.
eletriptan eql pharma 20 mg filmdragerad tablett
eql pharma ab - eletriptanhydrobromid - filmdragerad tablett - 20 mg - para-orange aluminiumlack hjälpämne; laktosmonohydrat hjälpämne; eletriptanhydrobromid 24,23 mg aktiv substans
eletriptan eql pharma 40 mg filmdragerad tablett
eql pharma ab - eletriptanhydrobromid - filmdragerad tablett - 40 mg - para-orange aluminiumlack hjälpämne; eletriptanhydrobromid 48,46 mg aktiv substans; laktosmonohydrat hjälpämne
moxifloxacin double-e pharma 400 mg filmdragerad tablett
double-e pharma ltd. - moxifloxacin - filmdragerad tablett - 400 mg - moxifloxacin 400 mg aktiv substans
buprenorphine/naloxone g.l. pharma 8 mg/2 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 8 mg/2 mg - naloxonhydrokloriddihydrat 2,44 mg aktiv substans; buprenorfinhydroklorid 8,64 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne
buprenorphine/naloxone g.l. pharma 4 mg/1 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 4 mg/1 mg - mannitol hjälpämne; laktosmonohydrat hjälpämne; naloxonhydrokloriddihydrat 1,22 mg aktiv substans; buprenorfinhydroklorid 4,32 mg aktiv substans
buprenorphine/naloxone g.l. pharma 2 mg/0,5 mg resoriblett, sublingual
g.l. pharma gmbh - buprenorfinhydroklorid; naloxonhydrokloriddihydrat - resoriblett, sublingual - 2 mg/0,5 mg - buprenorfinhydroklorid 2,16 mg aktiv substans; naloxonhydrokloriddihydrat 0,61 mg aktiv substans; laktosmonohydrat hjälpämne; mannitol hjälpämne
fingolimod unimedic pharma 0,5 mg kapsel, hård
unimedic pharma ab - fingolimodhydroklorid - kapsel, hård - 0,5 mg - fingolimodhydroklorid 0,56 mg aktiv substans
dasatinib accordpharma
accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastiska medel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib. ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib. newly diagnosed ph+ all in combination with chemotherapy.
ciprofloxacin bmm pharma 250 mg filmdragerad tablett
bmm pharma ab - ciprofloxacinhydroklorid (monohydrat) - filmdragerad tablett - 250 mg - ciprofloxacinhydroklorid (monohydrat) 291,08 mg aktiv substans; propylenglykol hjälpämne - ciprofloxacin